Design issues in initial HIV-treatment trials: Focus on ACTG A5095

Antiviral Therapy

Volumn 11, Issue 6, 2006, Pages 751-760

  Ribaudo, Heather J ^a   Kuritzkes, Daniel R ^b   Schackman, Bruce R ^c   Acosta, Edward P ^d   Shikuma, Cecilia M ^e   Gulick, Roy M ^c  

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ARTICLE; CLINICAL RESEARCH; CLINICAL STUDY; CLINICAL TRIAL; DRUG SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL;

ANTI-HIV AGENTS; CLINICAL TRIALS, PHASE III; CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SAMPLE SIZE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33749334124     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. AIDSinfo [homepage on the Internet]. Maryland: U.S. Department of Health and Human Services. Guidelines for use of antiretroviral agents in HIV-infected adults and adolescents - January 28, 2000. Available from: http://aidsinfo.nih. gov/ContentFiles/AdultandAdolescentGL 01282000010.pdf
2. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA 2001; 285:1155-1163.
3. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999; 341:1865-1873.
4. Podzamczer D, Ferrer E, Consiglio E, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine study). Antivir Ther 2002; 7:81-90.
5. Moyle G, Pozniak A, Opravil M, et al. The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. J Acquir Immune Defic Syndr 2000; 23:128-137.
6. Eron J, Junod P, Becker S, et al. NZT 4002: 64 week analysis of combivir (COM)-based triple and quadruple therapy in antiretroviral-naive, HIV-1 infected subjects. XIII International AIDS Conference. 9-14 July 2000, Durban, South Africa. Abstract WeOrB608.
7. Saag MS, Cahn P, Raffi F, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA 2004; 292:180-189.
8. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-2046.
9. AIDSinfo [homepage on the Internet]. Maryland: U.S. Department of Health and Human Services. Guidelines for use of antiretroviral agents in HIV-infected adults and adolescents - May 4, 2006. Available from: http://aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf
10. Lakatos E, Lan KKG. A comparison of sample size methods for the log rank statistic. Stat Med 1992; 11:179-191.
11. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35:549-556.
12. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70:659-663.
13. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient; introduction and design. Br J Cancer. 1976; 34:585-612.
14. Jennison C, Turnbull BW. Group Sequential Methods with Application to Clinical Trials. New York: Chapman and Hall; 2000. pp. 197-204.
15. Pocock SJ. Group sequential methods in design and analysis of clinical trials. Biometrika 1977; 64:191-199.
16. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-739.
17. Fischl MA, Ribaudo HJ, Collier AC, et al. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis 2003; 188:625-634.
18. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293-2303.
19. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003; 349:2304-2315.
20. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
21. Gilbert PB, DeGruttola V, Hammer SM, et al. Virologic and regimen termination surrogate endpoints in AIDS clinical trials. JAMA 2001; 285:777-784.
22. Shih, W. Problems in dealing with missing data and informative censoring in clinical trials. Curr Control Trials Cardiovasc Med 2002; 3:4.
23. U.S. Food and Drug Administration: Center for Drug Evaluation and Research [homepage on the Internet]. Guidance for Industry: Antiretroviral Drugs Using Plasma HIV RNA Measurements Clinical Considerations for Accelerated and Traditional Approval - October 2002. Available from: http://www.fda.gov/cder/ guidance/3647fnl.htm
24. van Leth F, Lange JM. Use of composite end points to measure clinical events. JAMA 2003; 290:1456-1457; author reply 1457.
25. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 2003; 289:2554-2559.
26. Pocock SJ. Clinical Trials. A Practical Approach. New York: John Wiley and Sons; 1983. pp. 41-49.
27. Phillips AN, Walker AS. Drug switching and virologic-based endpoints in trials of antiretroviral drugs for HIV infection. AIDS 2004; 18:365-270.
28. Kim MY, Goldberg JD. The effects of outcome misclassification and measurement error on the design and analysis of therapeutic equivalence trials. Stat Med 2001; 20:2065-2078.
29. Cooper E. Designs of clinical trials: active standard-of-care (equivalence) trials. J Acquir Immune Defic Syndr 1990; 3 Suppl 2:S77-S81.
30. Khanlou H, Yeh V, Guyer B, Falamivudinerthing C. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naïve HIV-infected patients. AIDS Patient Care STDS 2005; 19:135-140.
31. Gallant JE, Rodriguez AE, Weinberg WG, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005; 192:1921-1930.
32. Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naïve, HIV-infected patients receiving a once daily triple-nucleoside regimen of didanosine, lamivudine, and tenofovir DF. 11th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Abstract 51.
33. Gilbert P, Ribaudo HJ, Greenberg L, et al. Considerations in choosing a primary virological endpoint for durability in AIDS antiretroviral trials. AIDS; 2000; 14:1961-1972.
34. Smeaton LM, DeGruttola VD, Robbins GK, et al. A strategy trial comparing consecutive treatment for HIV-1. Controlled Clinical Trials. 2001; 22:142-159.
35. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-2185.
36. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-2195.
37. Brambilla D, Reichelderfer PS, Bremer JW, et al. The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance Program. AIDS 1999; 13:2269-2279.
38. Nettles RE, Kieffer TL, Kown P, et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA 2005; 293:817-829.
39. Staszewski S, Sabin C, Dauer B, et al. Definition of loss of virological response in trials of antiretroviral drugs. AIDS 2003; 17:1997-1998.
40. Landau A, Batisse D, Van Huyen JP, et al. Efficacy and safety of combination therapy with interferon-A2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS 2000; 14:839-844.
41. Zylberberg H, Benhamou Y, Lagneaux JL, et al. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut 2000; 47:694-697.
42. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19:1-46.
43. Korzon AH, Chaloner K. Protocol Development. In: AIDS Clinical Trials. New York: Wiley-Liss, Inc.; 1995. pp 84-87.
44. De Luca A, Di Giambenedetto S, Maida I, et al. Triple-Nucleoside Regimens versus Efavirenz (letter). N Engl J Med 2000; 351:717-719.
45. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). Ann Intern Med 2005; 143:714-721.
46. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-1861.
47. Gulick R, Ribaudo H, Shikuma C, et al. ACTG 5095: zidovudine/lamivudine/ abacavir vs. zidovudine/lamivudine + efavirenz vs. zidovudine/lamivudine/ abacavir + efavirenz for initial HIV therapy. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 16-19 December 2005, Washington, DC. Abstract H-416a.
48. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292:251-265.
49. Gazzard B; on behalf of the BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). HIV Med 2005; 6 Suppl 2:1-61.
50. Hammer SM, Türmen T, Vareldzis B, et al. Antiretroviral guidelines for resource-limited settings: The WHO's public health approach. Nature Med 2002; 8:649-650.